Radium Development Berhad Announces Strategic Diversification into Healthcare Sector

Key Highlights

• Radium Development Berhad (“Radium”) proposes a major diversification into the healthcare sector, expanding from its current core business in property development.
• The Group plans to develop and operate a new 140-bed hospital in Melaka, scalable up to 200 beds, marking its first foray into healthcare.
• The estimated development cost for the hospital is approximately RM300 million, with funding expected from a mix of bank borrowings (up to 70%) and internally generated funds.
• The diversification is expected to have a material impact on the Group’s net assets and, once operational, could contribute significantly to earnings and net profits.
• The Group’s wholly-owned subsidiary, Radium Healthcare Sdn Bhd (RHSB), will oversee the healthcare business, while Radium Hospital Ayer Keroh Sdn Bhd (RHAK) will manage hospital development and operations.
• Dr Arun Kumar A/L Beshamber Nath, with extensive experience in hospital establishment and healthcare management, has been appointed CEO of RHSB and will lead the healthcare initiative.
• An Extraordinary General Meeting (EGM) is scheduled for 28 April 2026 for shareholders to vote on the proposed diversification.

Detailed Analysis

Background and Rationale

Radium’s revenue is currently 100% derived from property development, with an ongoing portfolio of projects worth over RM2 billion and a land bank of 63.29 acres. The Board recognizes the need to broaden its income base and enhance earnings visibility beyond the cyclical nature of property development. The healthcare sector, driven by demographic trends such as Malaysia’s ageing population, advances in medical technology, and increasing healthcare spending, presents a commercially viable opportunity. The Board believes that healthcare can generate recurring income and introduce long-term operating assets to Radium’s portfolio.

Hospital Project Details

• Location: Bukit Katil, Melaka, with strategic accessibility and proximity to key infrastructure.
• Hospital Capacity: Initial 140 beds, scalable to 200 beds.
• Development Timeline: Construction commenced in November 2025; hospital expected to be operational in the first half of 2028.
• Development Cost Breakdown:
  • Land and related costs: RM28 million
  • Construction and medical equipment: RM245 million
  • Professional fees: RM14 million
  • Statutory fees: RM13 million
  • Total: RM300 million
• Funding: Anticipated to be 70% financed by bank borrowings (RM210 million), increasing Group gearing from 0.13x to 0.41x, with the remainder from internal funds.

Regulatory Approvals and Project Status

• All necessary land acquisition and development approvals have been obtained or are in process, including building plan approval and fire safety certification.
• The Ministry of Health licensing process for the hospital is underway, with the Borang 1 application already submitted. Further regulatory steps are expected to be completed in time for the hospital’s opening.

Management and Execution

• Dr Arun, a seasoned healthcare executive and ENT specialist, will spearhead the healthcare business, drawing on experience from previous roles at Manipal Hospital, Sunway Medical Centre, and Bukit Tinggi Medical Centre.
• The Group intends to expand its healthcare management team and staff as needed to support the new business segment.

Financial Impact and Shareholder Considerations

• The hospital is not expected to contribute materially to profits immediately, but as construction progresses, capitalized development costs will significantly affect Radium’s net assets.
• Upon hospital commencement, the healthcare business may contribute 25% or more of net profits and net assets, potentially transforming Radium’s earnings profile.
• No new shares will be issued for this diversification, so there will be no dilution of existing shareholders.
• Radium’s borrowings will increase, impacting gearing ratios, but this is anticipated and manageable.
• No directors, major shareholders, or connected persons have any direct or indirect interest in the diversification, ensuring governance integrity.

Risk Factors

• Business Diversification Risks: Radium will be exposed to new risks inherent in healthcare, including regulatory, operational, and market uncertainties.
• Competition Risks: The new hospital will face competition from existing and new private healthcare providers.
• Development Risks: Delays or cost overruns in hospital construction could impact profitability and cash flow.
• Key Personnel Risks: Dependence on Dr Arun and other key management personnel is significant; loss could impact execution and performance.
• Operational Risks: Clinical errors, medical negligence, and staff shortages are potential risks. The Group intends to mitigate these with insurance and robust governance frameworks.
• Political, Economic, and Regulatory Risks: Changes in government policy, economic downturns, or new regulations could impact the viability and profitability of the healthcare venture.

Shareholder Actions and EGM

• The EGM to vote on the diversification is scheduled for 28 April 2026. Shareholders are urged to review all details and participate in the vote, as this proposal could materially affect the company’s direction and future value.
• Proxy voting is available via hard copy or electronic submission; details and deadlines are provided in the circular.

Implications for Share Price

This announcement is potentially price-sensitive. If approved, Radium will transform from a pure property developer into a diversified group with a significant presence in the healthcare sector. The RM300 million hospital project could materially impact Radium’s future earnings, net assets, and risk profile. Investors should monitor developments, regulatory approvals, and hospital construction progress closely, as successful execution could unlock new recurring revenue streams and drive long-term shareholder value.

Disclaimer

This article is for informational purposes only and does not constitute investment advice. Investors should review the full circular and consult their own financial advisors before making any investment decisions related to Radium Development Berhad. All forward-looking statements are subject to risks and uncertainties as detailed above.

View RADIUM DEVELOPMENT BERHAD Historical chart here